4
Changes in Ownership
Protalix BioTherapeutics, Inc. Filed Acc 0001144204-18-049515
Options or other derivatives
- Executive VP, R&D acquired 700,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Shaaltiel Yoseph Executive VP, R&D | 2018-09-13 | Grant or award · Stock Options (Right to Buy) | +700,000 | 700,000 | D | ||
Loading xslF345X03/tv502880_4.xml…